Fig. 1From: Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center studyProgression-free survival in all patients. Kaplan–Meier curve of progression-free survival (PFS) of fulvestrant and trastuzumab combination therapy in patients with hormone receptor- and human epidermal growth factor receptor 2-positive metastatic breast cancerBack to article page